SG11201909079PA - Compounds useful as inhibitors of alcat 1 - Google Patents
Compounds useful as inhibitors of alcat 1Info
- Publication number
- SG11201909079PA SG11201909079PA SG11201909079PA SG11201909079PA SG 11201909079P A SG11201909079P A SG 11201909079PA SG 11201909079P A SG11201909079P A SG 11201909079PA SG 11201909079P A SG11201909079P A SG 11201909079PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- co7d
- inhibitors
- pct
- wuhan
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 101001047677 Homo sapiens Lysocardiolipin acyltransferase 1 Proteins 0.000 abstract 1
- 208000035342 Isolated congenital onychodysplasia Diseases 0.000 abstract 1
- 102100024033 Lysocardiolipin acyltransferase 1 Human genes 0.000 abstract 1
- 230000018109 developmental process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002431 foraging effect Effects 0.000 abstract 1
- 201000010158 nonsyndromic congenital nail disorder 7 Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479960P | 2017-03-31 | 2017-03-31 | |
| PCT/EP2018/058225 WO2018178304A1 (fr) | 2017-03-31 | 2018-03-29 | Composés utiles en tant qu'inhibiteurs d'alcat 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909079PA true SG11201909079PA (en) | 2019-10-30 |
Family
ID=61911570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909079P SG11201909079PA (en) | 2017-03-31 | 2018-03-29 | Compounds useful as inhibitors of alcat 1 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11208404B2 (fr) |
| EP (1) | EP3601274A1 (fr) |
| JP (1) | JP7208649B2 (fr) |
| CN (1) | CN110709394A (fr) |
| AU (2) | AU2018246341B2 (fr) |
| BR (1) | BR112019020252A2 (fr) |
| CA (1) | CA3058533A1 (fr) |
| EA (1) | EA201992302A1 (fr) |
| IL (1) | IL269695A (fr) |
| SG (1) | SG11201909079PA (fr) |
| WO (1) | WO2018178304A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018178304A1 (fr) * | 2017-03-31 | 2018-10-04 | Perenna Pharmaceuticals, Inc. | Composés utiles en tant qu'inhibiteurs d'alcat 1 |
| WO2020159576A1 (fr) | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Activateurs de la mitofusine et leurs procédés d'utilisation |
| AU2020215510A1 (en) | 2019-01-28 | 2021-07-22 | Mitochondria Emotion, Inc. | Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof |
| CN111848599B (zh) * | 2020-04-28 | 2022-04-12 | 江南大学 | 一类含氧五元杂环化合物、合成方法、药物组合物及用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0619733A2 (pt) * | 2005-12-12 | 2011-10-11 | Genelabs Tech Inc | compostos antivirais de n-(anel aromático de 6 membros)-amido |
| TW200811155A (en) * | 2006-05-30 | 2008-03-01 | Glaxo Group Ltd | Compounds |
| US20090105240A1 (en) * | 2007-10-17 | 2009-04-23 | Tomas Mustelin | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same |
| WO2009086303A2 (fr) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
| AU2010327936B2 (en) * | 2009-12-11 | 2015-08-20 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| KR20130074524A (ko) * | 2011-12-26 | 2013-07-04 | 한미약품 주식회사 | 신규 페닐 옥사디아졸 유도체 및 이를 포함하는 약학 조성물 |
| WO2013123305A1 (fr) | 2012-02-16 | 2013-08-22 | The Penn State Research Foundation | Modulateurs de l'acyl-coa lysocardiolipine acyltransférase 1 (alcat1) et leurs utilisations |
| WO2014055644A2 (fr) | 2012-10-02 | 2014-04-10 | New York University | Compositions pharmaceutique et traitement de maladies génétiques associées à une désintégration d'arn à médiation non-sens |
| CA2916977A1 (fr) | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methodes et compositions destinees a detecter et a diagnostiquer des maladies et des affections |
| WO2014210319A2 (fr) * | 2013-06-26 | 2014-12-31 | The Trustees Of Columbia University In The City Of New York | Inhibiteurs du transporteur de nucléosides équilibrant de type 1 de plasmodium falciparum en tant que composés anti-parasitaires |
| WO2018178304A1 (fr) * | 2017-03-31 | 2018-10-04 | Perenna Pharmaceuticals, Inc. | Composés utiles en tant qu'inhibiteurs d'alcat 1 |
-
2018
- 2018-03-29 WO PCT/EP2018/058225 patent/WO2018178304A1/fr unknown
- 2018-03-29 AU AU2018246341A patent/AU2018246341B2/en active Active
- 2018-03-29 EP EP18716186.4A patent/EP3601274A1/fr active Pending
- 2018-03-29 EA EA201992302A patent/EA201992302A1/ru unknown
- 2018-03-29 CN CN201880027862.XA patent/CN110709394A/zh active Pending
- 2018-03-29 CA CA3058533A patent/CA3058533A1/fr active Pending
- 2018-03-29 JP JP2020503354A patent/JP7208649B2/ja active Active
- 2018-03-29 SG SG11201909079P patent/SG11201909079PA/en unknown
- 2018-03-29 US US16/499,851 patent/US11208404B2/en active Active
- 2018-03-29 BR BR112019020252A patent/BR112019020252A2/pt not_active IP Right Cessation
-
2019
- 2019-09-26 IL IL26969519A patent/IL269695A/en unknown
-
2021
- 2021-09-29 US US17/489,590 patent/US20220089582A1/en active Pending
-
2022
- 2022-09-20 AU AU2022235533A patent/AU2022235533B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022235533A1 (en) | 2022-10-13 |
| BR112019020252A2 (pt) | 2020-04-22 |
| EA201992302A1 (ru) | 2020-02-27 |
| AU2018246341B2 (en) | 2022-07-07 |
| IL269695A (en) | 2019-11-28 |
| CA3058533A1 (fr) | 2018-10-04 |
| JP7208649B2 (ja) | 2023-01-19 |
| AU2022235533B2 (en) | 2024-05-30 |
| US11208404B2 (en) | 2021-12-28 |
| US20200109136A1 (en) | 2020-04-09 |
| US20220089582A1 (en) | 2022-03-24 |
| AU2018246341A1 (en) | 2019-11-14 |
| CN110709394A (zh) | 2020-01-17 |
| WO2018178304A1 (fr) | 2018-10-04 |
| EP3601274A1 (fr) | 2020-02-05 |
| JP2020515646A (ja) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201909079PA (en) | Compounds useful as inhibitors of alcat 1 | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201901528RA (en) | Proteolytically cleavable chimeric polypeptides and methods of use thereof | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
| SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| SG11201909395TA (en) | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201903450YA (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| SG11201408047XA (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| SG11201906238TA (en) | Split sector level sweep using beamforming refinement frames | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201806542PA (en) | Anti-mica antibodies | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |